Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135559 · ClinicalTrials.gov registry record · Phase 3
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
A Phase 3 study of Haemophilia A and B With and Without Inhibitors, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT05135559: Active Phase 3 study of Haemophilia A and B With and Without Inhibitors, sponsored by Novo Nordisk A/S.
NCT05135559 is a Phase 3 study of Haemophilia A and B With and Without Inhibitors that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 153 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05135559, a Phase 3 study of Haemophilia A and B With and Without Inhibitors, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Conditions Studied
Interventions
- DRUG Concizumab
Study Locations (20)
Florida
- Arnold Palmer Children's Hospital - Orlando
- Nemours Child Orlando Hem/Onc. - Orlando
Georgia
- Augusta Univ/Childrens Hosp-GA - Augusta
- Memorial Health University Medical Center - Savannah
Louisiana
- Children's Hosp-New Orleans - New Orleans
- Ochsner Clinic Foundation - New Orleans
Texas
- Cook Children's Hospital-Hematology-Oncology - Fort Worth
- Texas Children's Hospital_Houston - Houston
California
- Rady Childrens Hosp San Diego - San Diego
Colorado
- University of Colorado Hospital - Aurora
Illinois
- Childrens Hospital of Chicago - Chicago
Indiana
- Indiana Hemophilia-Thromb Ctr - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2029-11-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05135559
The ClinicalTrials.gov registry entry for NCT05135559 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Haemophilia A and B With and Without Inhibitors appearing as the primary indexed condition, and to 1 intervention - of which Concizumab is the first listed.
NCT05135559 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Georgia, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05135559 about?
NCT05135559 is a clinical study titled "A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors". This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin wi...
What is the current status of trial NCT05135559?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2022-03-24. Estimated completion is 2029-11-02.
What conditions does trial NCT05135559 study?
This clinical trial studies the following conditions: Haemophilia A and B With and Without Inhibitors.
What interventions are being tested in trial NCT05135559?
The interventions under investigation include: Concizumab (DRUG).
Who is sponsoring clinical trial NCT05135559?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05135559 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.